Zydus Scales Up Global Biologics Game with $125 Million U.S. Acquisition

is making a strategic leap by acquiring two biologics manufacturing facilities from Agenus Inc. in the U.S. for $125 million—a move that strengthens its global biotech footprint and accelerates its ambitions in the high-growth biologics space. What the Deal Brings: * Two fully operational biologics facilities in the U.S. * Expansion of monoclonal antibody (mAb) and cell line development capabilities * Access to advanced manufacturing platforms supporting large-scale commercial production * Strategic base to serve both regulated markets and future pipeline assets Industry Insight: Biologics—especially mAbs, biosimilars, and novel biologic entities—are the future of pharma, commanding over 40% of global drug spend and growing at double the rate of small molecules. Zydus’ entry aligns with a broader India-to-Global pharma trend, where Indian firms: * Seek vertical integration to control biologics R&D to manufacturing * Invest in U.S. or EU assets to reduce time-to-market and regulatory friction * Prepare for the next wave of biosimilar opportunities as more patents expire by 2030 What This Means for Investors: Zydus is no longer just a generics player—this deal places it in a stronger position to: * Capture high-margin biologics opportunities * Compete in U.S. markets with robust, local manufacturing * Attract CDMO (Contract Development and Manufacturing Organization) opportunities globally Bottom Line: Zydus’ latest move isn’t just an acquisition—it's a positioning play for the biotech decade ahead. Source: The Hindu No Recommendations